

Roll Back Malaria: Partnership in Action

Sumitomo Chemical is an active member in the **Roll Back Malaria Partnership**, a broad coalition of endemic countries, agencies, the private sector and other organizations and foundations who are fighting malaria with the goal of halving the number of deaths from the disease by 2010. Sumitomo Chemical partners with **Millennium Villages**, the pioneering effort by Jeffrey Sachs, and **Malaria No More** in major projects. It also provides nets to the largest anti-malaria initiatives, including the **President's Malaria Initiative** (U.S.) and the child-centred work of UNICEF. Endemic countries worldwide buy long lasting insecticide treated nets with grants from the **Global Fund to Fight AIDS, Tuberculosis and Malaria**. Olyset is the only long-lasting insecticide-treated net with a full recommendation from the **World Health Organization**.

Current impact of the disease:

- The toll of malaria, a preventable and treatable disease, is unacceptable: it kills over 3,000 children every day
- 1-3 million deaths per year. Between 350–500 million people fall ill
- Perpetuates cycle of poverty, costing Africa U.S. \$12B per year in lost GDP
- 100% coverage in the 30 hardest-hit African countries could be achieved with 68 million LLINs/year for four years, at a cost of \$3.4 billion.* It has been shown that 80% LLIN coverage is sufficient to drastically reduce transmission rates.

For under U.S.\$10 a child can be protected from infection for five years with long-lasting insecticidal nets , and for less than U.S.\$6 an adult can be cured with artemisinin-based combination therapy (ACT) drugs

New progress:

- Growing resources, political commitment, and multi-sector cooperation are making large-scale, comprehensive programs feasible and saving lives now
- President's Malaria Initiative (U.S.\$1.2B over five years)
- Global Fund (U.S.\$2.6B committed to date)
- World Bank (U.S.\$500M over three years)
- Annual supply of insecticide-treated nets more than doubled from 30 million nets in 2004 to 63 million nets in 2006
- Global procurement of artemisinin combination therapies grew from 3 million doses in 2003 to 100 million in 2006
- Promising research and development progress – drugs, vaccines, vector control

Rapid Scale-up is Most Cost-Effective Approach*

- Affordable and technically achievable
- Would save twice as many lives per dollar spent
 - 2.5 million additional lives saved
 - Prevent more than 430 million additional malaria cases
- Would produce dramatic economic output
 - \$50 billion increase over five years
- Springboard to long-term goal of eradicating malaria

* "We Can't Afford to Wait: The Business Case for Rapid Scale-up of Malaria Control in Africa," prepared by Malaria No More and McKinsey & Co. on behalf of RBM, January 2008